Evidence map›Paper›PMID 42337543›Full record

Trial reportBMC complementary medicine and therapies2026

Patterns of complementary and alternative medicine use and factors influencing its utilization in thyroid cancer: findings from the MASTER study.

Han-Sang Baek, Mijin Kim, Kyungsik Kim, Woojin Lim, Kwangsoon Kim, Ja Seong Bae, Dong-Jun Lim, Eun-Jae Chung, Bon Seok Koo, Sung Yong Choi and 7 more

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Han-Sang Baek *Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Uijeongbu St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-6896-9024
Mijin Kim *Department of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.ORCID http://orcid.org/0000-0002-1538-8859
Kyungsik KimDepartment of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongro-gu, Seoul, 03080, Korea.ORCID http://orcid.org/0000-0001-9007-7025
Woojin LimDepartment of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongro-gu, Seoul, 03080, Korea.ORCID http://orcid.org/0000-0001-8305-0246
Kwangsoon KimDepartment of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0001-6403-6035
Ja Seong BaeDepartment of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0002-6271-2105
Dong-Jun LimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.ORCID http://orcid.org/0000-0003-0995-6482
Eun-Jae ChungDepartment of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0003-3918-7717
Bon Seok KooDepartment of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Chungnam National University, Daejeon, Korea.ORCID http://orcid.org/0000-0002-5928-0006
Sung Yong ChoiDepartment of Otorhinolaryngology-Head and Neck Surgery, National Cancer Center, Goyang, Korea.ORCID http://orcid.org/0000-0002-4865-5677
Eun Kyung LeeDepartment of Internal Medicine, Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.ORCID http://orcid.org/0000-0003-0098-0873
Eu Jeong KuDivision of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul National University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0001-5533-4989
Kyeong Jin KimDivision of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0002-5878-6005
Hee Kyung KimDepartment of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea.ORCID http://orcid.org/0000-0002-1617-3171
June Young ChoiSeoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea.ORCID http://orcid.org/0000-0001-9990-607X
Bo Hyun KimDepartment of Internal Medicine, Biomedical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea. pons71@hanmail.net.ORCID http://orcid.org/0000-0001-9632-9457
Sue K ParkDepartment of Preventive Medicine, Seoul National University College of Medicine, 103 Daehak-ro, Jongro-gu, Seoul, 03080, Korea. suepark@snu.ac.kr.ORCID http://orcid.org/0000-0001-5002-9707

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundComplementary and alternative medicine (CAM) therapies are increasingly popular; however, comprehensive data on their usage patterns and types remain limited, especially in South Korea. We investigated the patterns and economic impact of CAM use in thyroid cancer after lobectomy.

methodsWe utilized data from the MASTER study, a prospective, multicenter, randomized, controlled trial on patients with differentiated thyroid cancer post-lobectomy. Data on CAM usage in 1,166 patients at baseline and at 3, 6, and 12 months postoperatively were included. Logistic regression quantified the effect of levothyroxine treatment on CAM usage.

resultsCAM use was reported by 58% of participants. Dietary nutritional products were the most used CAM modality, with usage rates of 42.5% at baseline, decreasing to 37.7% at 12 months. Exercise and physical therapies also showed significant differences, with 19.2% using these modalities at baseline, increasing to 27.1% at 12 months. The median cost for CAM varied, with dietary products consistently costing 144 USD (200,000 KRW) and exercise costs rising from 144 USD (200,000 KRW) to 288 USD (400,000 KRW) over time. Patients on levothyroxine were less likely to use CAM, with an odds ratio (OR) of 0.57 (95% confidence interval [CI] = 0.45-0.72, P < 0.001). However, levothyroxine users who did use CAM were more likely to use multiple CAM modalities, with an OR of 3.66 (95% CI = 1.88-7.14, P = 0.001) at baseline, though this association did not remain significant later.

conclusionsCAM is integrated into thyroid cancer treatment, indicating a need for healthcare professionals to discuss its safety and effective care integration.

Indexed as

Complementary TherapiesThyroid NeoplasmsAdultFemaleHumansMaleMiddle AgedProspective StudiesRepublic of KoreaThyroxineThyroxineComplementary and alternative medicineMASTER studyThyroid cancer

Identifiers

PMID42337543
PMCPMC13543374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.